Australian Antimicrobial Resistance Network - AAMRNet

In September 2020, MTPConnect announced the formation of an Australian-first network bringing together key stakeholders to address the impact of antimicrobial resistance (AMR) on human health.

The Australian Antimicrobial Resistance network - AAMRNet – has been established following recommendations in a new report, ‘Fighting Superbugs: A Report on the Inaugural Meeting of Australia’s Antimicrobial Resistance Stakeholders’, also released by MTPConnect and prepared in partnership with Biointelect.

Antimicrobial resistance occurs when microbes such as bacteria become resistant to drugs which once killed them, evolving to become untreatable ‘superbugs’.

Website: AAMRNet  |  Join AAMRNet, by contacting MTPConnect  |  Twitter: @AAMRNet_


State: Victoria

Consortium lead: MTPConnect

Industry contributions by: Pfizer ANZ, CSIRO, MSD Australia, GSK Australia, Botanix Pharmaceuticals, Recce Pharmaceuticals, SpeeDx, Biointelect, Monash Centre to Impact AMR, and Medicines Australia

MTPConnect grant: $469,367

Industry contributions: $781,000

Project duration: September 2020 - June 2023 Completed

Additional partners of the AAMRNet include: DMTC, GARDP, AusBiotech, Roche Diagnostics Australia, Menzies School of Health Research, Formulytica, Epichem, BiomeBank, CO-ADD, Monash Biomedicine Discovery Institute and RESULTS International Australia.



On the final day of World Antimicrobial Awareness Week 2021 (WAAW) the AMRelay 2021 took place - a 24 hour virtual and global event organised by the AMR Insights Ambassador Network - offering a series of consecutive contributions from stakeholders in the AMR sector. AAMRNet Co-Chair Andrew Bowskill presented an update on Australia’s first industry led, multi-stakeholder Antimicrobial Resistance Network, established and operated by MTPConnect to support actions to combat AMR in Australia. Watch the video below: